Quinine hydrobromide

Cat. No.:	HY-B1751C
CAS No.:	549-49-5
Molecular Formula:	$C_{20}H_{25}BrN_2O_2$
Molecular Weight:	405.33
Target:	Parasite; Cytochrome P450; Potassium Channel
Pathway:	Anti-infection; Metabolic Enzyme/Protease; Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Quinidine hydrobromide is an antiarrhythmic agent. Quinidine is a potent, orally active, selective cytochrome P450db inhibitor. Quinidine hydrobromide is also a K^+ channel blocker with an IC_{50} of 19.9 μM. Quinidine hydrobromide can be used for malaria research[1][2][3].

In Vitro

Quinidine hydrobromide is an anti-arrythmic drug which affects ionic currents in heart muscle and which has also been shown to be a potent blocker of several classes of K^+ channel in a variety of cell types[1].
Bath application of quinidine hydrobromide causes a dose-dependent reduction of the peak amplitude of I_k. The K_d for blockade of I_k at 0 mV is estimated to be 41 μM[1].
Quinidine hydrobromide elicits a dose-dependent increase of the rate of the decay of I_k and this effect is enhanced by membrane depolarization. Quinidine also causes a 5 mV hyperpolarizing shift of the steady-state inactivation curve and increases the half-time for recovery from inactivation. Quinidine hydrobromide does not affect the onset of inactivation measured at -30 mV[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Quinidine hydrobromide is rapidly absorbed, with peak plasma concentrations 60-90 min after an oral dose. Other salts (gluconate, polygalacturonate) are more slowly absorbed, with lower peak concentrations[2].
Quinidine hydrobromide is approximately 70-90 % bound to plasma proteins. It undergoes hepatic oxidative metabolism to form an N-oxide, a 3-hydroxy form, an O-demethyl form and 2'-quinidinone[2].
Quinidine hydrobromide inhibits metabolism of amphetamine in rats. Quinidine hydrobromide pretreatment results in a significant decrease in the excretion of p-hydroxyamphetamine at 24 and 48 h to 7.2 and 24.1% of the vehicle-control levels, respectively, accompanied by a significant increase in amphetamine excretion between 24 and 48 h to 542% of the control[3].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Mol Med Rep. 2021 Mar 2.
- Norwegian University of Science and Technology, Faculty of Medicine and Health sciences. 2019 Sep.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Kehl SJ, et al. Quinidine-induced inhibition of the fast transient outward K+ current in rat melanotrophs. Br J Pharmacol. 1991 Jul;103(3):1807-13.

[2]. Roden DM, et al. Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA